Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;20(5):24.
doi: 10.3892/etm.2020.9152. Epub 2020 Aug 28.

Comparison of the effectiveness and safety of travoprost and latanoprost for the management of open-angle glaucoma given as an evening dose

Jing Li  1 , Xiaoyi Wang  1 , Guihua Xu  1 , Ruidong Deng  1 , Laiwei Wu  1 , Liqin Zhang  1 , Zilin Chen  1
Affiliations

Comparison of the effectiveness and safety of travoprost and latanoprost for the management of open-angle glaucoma given as an evening dose

Jing Li et al. Exp Ther Med. 2020 Nov.

Abstract

As intraocular pressure (IOP) is primarily higher in the morning, an evening dose of prostaglandin analogs is typically used as monotherapy to decrease IOP in patients with open-angle glaucoma. Travoprost (TV) has reported efficacy in treating open-angle glaucoma; however, the safety and efficacy may be different compared with that for latanoprost (LT). The aim of the present study was to compare the effectiveness and safety of an evening dose of TV compared with that of LT in treating open-angle glaucoma. Data including IOP, results of lid and slit-lamp examination and ophthalmoscopy, as well as adverse effects in 250 affected eyes from patients with open-angle glaucoma who received either TV (n=89) or LT (n=161) once in the evening for 3-months were included in the analyses. At the end of treatment, TV (23.45±1.52 vs. 19.15±1.01 mmHg; P<0.0001) and LT (23.93±2.11 vs. 19.45±1.11 mmHg; P<0.0001) successfully lowered the IOP. In addition, there was no significant difference in the reduction of IOP values at the end of treatment between the two groups (P=0.120). Furthermore, there were no adverse effects on visual acuity (P>0.05), except for non-visual acuity, for example hyperemia (P<0.0001 for both groups), while there was a significant increase in the number of patients with dry eyes receiving TV (P=0.020) and a significant increase with eyelid swelling (P=0.036) and headache (P=0.037) in patients receiving LT. In conclusion, evening doses of TV and LT had the same efficacy and manageable adverse effects in the treatment of open-angle glaucoma (level of evidence, 3).

Keywords: evening dosing; hyperemia; intraocular pressure; latanoprost; open-angle glaucoma; travoprost.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the present study.
Figure 2
Figure 2
Evaluation of hyperemia and conjunctival staining in6areas of the eye.
Figure 3
Figure 3
Evaluation of corneal staining in5areas of the cornea.
Figure 4
Figure 4
Intraocular pressure in the two groups at different time-points. Values are expressed as the mean ± standard deviation. *P<0.05 vs. BL. The mean of all three measurements [morning (10 am), noon (2 pm) and evening (6 pm)] was used for the analysis. BL, at the start of treatment during a routine check-up; EL, at the end of 3-months of the treatment; TV, travoprost; LT, latanoprost.
Figure 5
Figure 5
Hyperemia in the two groups at different time-points. Values (staining intensity score) are expressed as the mean ± standard deviation. *P<0.05 vs. BL. Staining was scored as follows: 0, Absent; 1, mild staining; 2, moderate staining; and 3, severe staining (maximum possible). BL, at the start of treatment during a routine check-up; EL, at the end of 3-months of the treatment; TV, travoprost; LT, latanoprost.
Figure 6
Figure 6
Results of corneal staining evaluation at the end of 3-months of treatment. Values (staining intensity score) are expressed as the mean ± standard deviation. Staining was scored as follows: 0, Absent; 1, mild staining; 2, moderate staining; and 3, severe staining (maximum possible).
Figure 7
Figure 7
Results of conjunctival staining evaluation at the end of 3-months of treatment. Values are expressed as the mean ± standard deviation. 0, Absent; 1, mild staining; 2, moderate staining; and 3, severe staining (maximum possible).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ayala M, Chen E. The influence of topical prostaglandin analogues in inflammation after selective laser trabeculoplasty treatment. J Ocul Pharmacol Ther. 2012;28:118–122. doi: 10.1089/jop.2011.0084. - DOI - PMC - PubMed
    1. Zhang XL, Qin L. Efficacy of travoprost for the treatment of patients with glaucoma. Medicine (Baltimore) 2019;98(e16526) doi: 10.1097/MD.0000000000016526. - DOI - PMC - PubMed
    1. Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, Sunaric-Mégevand G, Rossetti L. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefes Arch Clin Exp Ophthalmol. 2016;254:1151–1158. doi: 10.1007/s00417-016-3299-9. - DOI - PubMed
    1. Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477–485. doi: 10.1001/archopht.122.4.477. Eye Diseases Prevalence Research Group. - DOI - PubMed
    1. Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan KY. National and subnational prevalence and burden of glaucoma in China: A systematic analysis. J Glob Health. 2017;7(020705) doi: 10.7189/jogh.07.020705. - DOI - PMC - PubMed